Radiation and inhibition of angiogenesis by canstatin synergize to induce HIF-1α-mediated tumor apoptotic switch

Journal of Clinical Investigation

Volumn 117, Issue 7, 2007, Pages 1844-1855

  Magnon, Claire ^a,f   Opolon, Paule ^a   Ricard, Marcel ^a   Connault, Elisabeth ^a   Ardouin, Patrice ^a   Galaup, Ariane ^b,c   Métivier, Didier ^b   Bidart, Jean Michel ^a   Germain, Stéphane ^b,c,d   Perricaudet, Michel ^a,e   Schlumberger, Martin ^a,e  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b INSERM   (France)

^c l'alimentation et l'Environnement   (France)

^d HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^e UNIVERSITÉ PARIS SACLAY   (France)

^f MOUNT SINAI HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANSTATIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; RADIOACTIVE IODINE;

ANGIOGENESIS; ANIMAL CELL; ANIMAL MODEL; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER SURVIVAL; CELL DEATH; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; HYPOXIA; IN SITU HYBRIDIZATION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIATION; SCINTIGRAPHY; TETRAPLOIDY; TUMOR MODEL; TUMOR RESISTANCE; TUMOR VOLUME;

ADENOVIRIDAE; ANIMALS; APOPTOSIS; CELL LINE; COLLAGEN TYPE IV; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE THERAPY; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; INTEGRINS; MICE; MICE, TRANSGENIC; MITOCHONDRIA; NEOPLASMS; PEPTIDE FRAGMENTS; SIGNAL TRANSDUCTION; SYMPORTERS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 34447132029     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI30269     Document Type: Article

References (49)

1. Schlumberger, M. 1998. Papillary and follicular thyroid carcinoma. N. Engl. J. Med. 338:297-306.
2. Cooper, D.S., et al. 2006. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 16:109-142.
3. Dai, G., Levy, O., and Carrasco, N. 1996. Cloning and characterization of the thyroid iodide symporter. Nature. 379:458-460.
4. Eskandari, S., et al. 1997. Thyroid Na+/I- symporter. Mechanism, stoichiometry, and specificity. J. Biol. Chem. 272:27230-27238.
5. Filetti, S., et al. 1999. Sodium/iodide symporter: a key transport system in thyroid cancer cell metabolism. Eur. J. Endocrinol. 141:443-457.
6. Shimura, H., Haragushi, K., Miyazaki, A., Endo, T., and Onaya, T. 1997. Iodide uptake and experimental 131I therapy in transplanted undifferentiated thyroid cancer cells expressing the Na+/I- symporter gene. Endocrinology. 138:4493-4496.
7. Spitzweg, C., et al. 2000. Treatment of prostate cancer by radioiodine therapy after tissue-specific expression of the sodium iodide symporter. Cancer Res. 60:6526-6530.
8. Smit, J.W.A., et al. 2000. Reestablishment of in vitro and in vivo iodide uptake by transfection of the human sodium iodide symporter in a hNIS defective human thyroid carcinoma cell line. Thyroid. 10:939-943.
9. Boland, A., et al. 2000. Adenovirus-mediated transfer of the thyroid sodium/iodide symporter gene into tumors for a targeted radiotherapy. Cancer Res. 60:3484-3492.
10. Dingli, D., et al. 2003. Genetically targeted radiotherapy for multiple myeloma. Blood. 102:489-496.
11. Schipper, M.L., et al. 2003. Radioiodide treatment after sodium iodide symporter gene transfer is a highly effective therapy in neuroendocrine tumor cells. Cancer Res. 63:1333-1338.
12. Garcia-Barros, M., et al. 2003. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science. 300:1155-1159.
13. Moeller, B.J., Cao, Y., Li, C.Y., and Dewhirst, M.W. 2004. Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules. Cancer Cell. 5:429-441.
14. Gorski, D.H., et al. 1999. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res. 59:3374-3378.
15. Abdollahi, A., et al. 2003. SU5416 and SU6668 attenuate the angiogenic effects of radiation-induced tumor cell growth factor production and amplify the direct anti-endothelial action of radiation in vitro. Cancer Res. 63:3755-3763.
16. Mauceri, H.J., et al. 1998. Combined effects of angiostatin and ionizing radiation in antitumor therapy. Nature. 394:287-291.
17. Griscelli, F., et al. 2000. Combined effects of radiotherapy and angiostatin gene therapy in glioma tumor model. Proc. Natl. Acad. Sci. U. S. A. 97:6698-6703.
18. Lee, C.G., et al. 2000. Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res. 60:5565-5570.
19. Salloum, R.M., et al. 2000. NM-3, an isocoumarin, increases the antitumor effects of radiotherapy without toxicity. Cancer Res. 60:6958-6963.
20. Geng, L., et al. 2001. Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy. Cancer Res. 61:2413-2419.
21. Griffin, R.J., et al. 2002. Simultaneous inhibition of the receptor kinase activity of vascular endothelial, fibroblast, and platelet-derived growth factors suppresses tumor growth and enhances tumor radiation response. Cancer Res. 62:1702-1706.
22. Gorski, D.H., et al. 2003. Prolonged treatment with angiostatin reduces metastatic burden during radiation therapy. Cancer Res. 63:308-311.
23. Carmeliet, P., et al. 1998. Role of HIF-1a in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature. 394:485-490.
24. Harris, A.L. 2002. Hypoxia - a key regulatory factor in tumour growth. Nat. Rev. Cancer. 2:38-47.
25. Greijer, A.E., and Van der Wall, E. 2004. The role of hypoxia inducible factor 1 (HIF-1) in hypoxia induced apoptosis. J. Clin. Pathol. 57:1009-1014.
26. v integrins. Science. 270:1500-1502.
27. Kamphaus, G.D., et al. 2000. Canstatin, a novel matrix-derived inhibitor of angiogenesis and tumor growth. J. Biol. Chem. 275:1209-1215.
28. Panka, D.J., and Mier, J.W. 2003. Canstatin inhibits Akt activation and induces Fas-dependent apoptosis in endothelial cells. J. Biol. Chem. 278:37632-37636.
29. 5 integrins. Cancer Res. 65:4353-4361.
30. Spitzweg, C., et al. 2001. In vivo sodium iodide symporter gene therapy of prostate cancer. Gene Ther. 8:1524-1531.
31. Wykoff, C.C., et al. 2000. Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res. 60:7075-7083.
32. Kops, G.J., Weaver, B.A., and Cleveland, D.W. 2005. On the road to cancer: aneuploidy and the mitotic checkpoint. Nat. Rev. Cancer. 5:773-785.
33. Fujiwara, T., et al. 2005. Cytokinesis failure generating tetraploids promotes tumorigenesis in p53-null cells. Nature. 437:1043-1047.
34. Okada, H., and Mak, T.W. 2005. Pathways of apoptotic and non-apoptotic death in tumour cells. Nat. Rev. Cancer. 4:592-603.
35. Tao, W., et al. 2005. Induction of apoptosis by an inhibitor of the mitotic kinesin KSP requires both activation of the spindle assembly checkpoint and mitotic slippage. Cancer Cell. 8:49-59.
36. Bergers, G., Javaherian, K., Lo, K.M., Folkman, J., and Hanahan, D. 1999. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science. 284:808-812.
37. Robbins, R.J., and Schlumberger, M.J. 2005. The evolving role of (131)I for the treatment of differentiated thyroid carcinoma. J. Nucl. Med. 46(Suppl. 1):28S-37S.
38. Wiseman, G.A., and Kvols, L.K. 1995. Therapy of neuroendocrine tumors with radiolabeled MIBG and somatostatin analogues. Semin. Nucl. Med. 25:272-278.
39. Mazure, N., Chen, E.Y., Laderoute, K.R., and Giaccia, A.J. 1997. Induction of vascular endothelial growth factor by hypoxia is modulated by PI3K/Akt signaling pathway in Ha-ras-transformed cells through a hypoxia inducible factor-1 transcriptional element. Blood. 90:3322-3331.
40. Chandel, N.S., et al. 2000. Reactive oxygen species generated at mitochondrial complex III stabilize hypoxia-inducible factor-1a during hypoxia. J. Biol. Chem. 275:25130-25138.
41. Cowden Dahl, K.D., Robertson, S.A., Weaver, V.M., and Simon, M.C. 2005. Hypoxia-inducible factor regulates ?v?3 integrin cells surface expression. Mol. Biol. Cell. 16:1901-1912.
42. Weaver, B.A.A., and Cleveland, D.W. 2005. Decoding the links between mitosis, cancer and chemotherapy: the mitotic checkpoint, adaptation and cell death. Cancer Cell. 8:7-12.
43. Castedo, M., et al. 2004. Mitotic catastrophe constitutes a special case of apoptosis whose suppression entails aneuploidy. Oncogene. 23:4362-4370.
44. Taylor, W.R., and Stark, G.R. 2001. Regulation of the G2/M transition by p53. Oncogene. 20:1803-1815.
45. Iliopoulos, O., Kibel, A., Gray, S., and Kaelin, W.G., Jr. 1995. Tumour suppression by the human von Hippel-Lindau gene product. Nat. Med. 1:822-826.
46. Penna, D., Schmidt, A., and Beermann, F. 1998. Tumors of the retinal pigment epithelium metastasize to inguinal lymph nodes and spleen in tyrosinase-related protein 1/SV40 T antigen transgenic mice. Oncogene. 17:2601-2607.
47. Elie, N., Plancoulaine, B., Signolle, J.P., and Herlin, P. 2003. A simple way of quantifying immunostained cell nuclei on the whole histological section. Cytometry A. 56:37-45.
48. Le Jan, S., et al. 2003. Angiopoietin-like 4 is a proangiogenic factor produced during ischemia and in conventional renal cell carcinoma. AJP. 162:1521-1528.
49. Berra, E., et al. 2003. HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1α in normoxia. EMBO J. 22:4082-4090.